Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC176 in Chinese Patients With mCRPC
NCT05673109Phase 1Terminated
- Sponsor
- Accutar Biotechnology, Inc.
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AC0176 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Accutar Biotechnology, Inc. Primary endpoints: Adverse events (AEs)/Serious adverse events (SAEs) at 24 months, Clinically significant abnormalities in vital signs at 24 months and 3 more. Started Feb 2023; status: terminated.
02
Drugs
AC0176
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05673109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673109.